A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
This study, called RELATIVITY-073, is a Phase 2 trial exploring a new treatment for advanced liver cancer. It involves adults whose cancer has worsened even after taking common first-line treatments called tyrosine kinase inhibitors, and who haven't yet tried other specific immune-boosting therapies. The study combines two medicines, nivolumab (brand name Opdivo) and relatlimab. Researchers want to understand how effective this combination is at shrinking tumors and controlling the disease. They will also carefully watch for any side effects to make sure the treatment is safe for patients. This is an important step in finding new ways to treat advanced liver cancer.
At a glance
What is this study about?
This study is looking for new ways to treat a type of advanced liver cancer called hepatocellular carcinoma. If you or someone you know has this condition, it means the cancer has grown and spread, and unfortunately, previous treatments called tyrosine kinase inhibitors haven't worked well enough.
The main goal of this study is to see how well a combination of two medicines, nivolumab (also known as Opdivo) and relatlimab, can help shrink tumors in people with advanced liver cancer. These medicines work by helping your body's own immune system fight the cancer. Researchers will carefully check how many patients respond to the treatment and for how long. They will also pay close attention to any side effects to understand how safe this new combination is.
By taking part, you could be helping doctors learn more about advanced liver cancer and find better treatments for patients in the future. It's a chance to potentially access new medicines that aren't widely available yet.
Key takeaways
- New combination treatment for advanced liver cancer.
- For patients whose prior treatments (tyrosine kinase inhibitors) haven't worked.
- Tests nivolumab (Opdivo) and relatlimab given together.
- Aims to check how well the treatment shrinks tumors and its safety.
- If eligible, you'd be contributing to future cancer research.
Who may be eligible?
To be considered for this study, you would need to be an adult, aged 18 or over. This study is open to both men and women.
An important part of who can join is your medical history. Specifically, the study is for people with advanced liver cancer that has continued to grow even after you've been treated with certain other cancer medications called tyrosine kinase inhibitors. You should not have received other specific types of immune-boosting treatments before.
Your study doctor will carefully review your full medical history and perform extra tests to make sure that this study is the right fit for you and safe for your health. There will be other specific health requirements that your doctor will discuss.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced liver cancer (hepatocellular carcinoma)?
- Has your cancer progressed despite treatment with tyrosine kinase inhibitors?
- Have you NOT received other types of immune-boosting cancer treatments (like PD-1/PD-L1 inhibitors or CTLA-4 inhibitors) before?
- Are you willing to have regular hospital visits, tests, and scans?
What does participation involve?
If you decide to take part, you would receive the study medications, nivolumab and relatlimab, as an infusion (given through a drip into your arm). The study period will involve regular visits to the clinic for these treatments and to monitor your health. These visits will include blood tests, physical examinations, and scans (like CT or MRI scans) to check how the cancer is responding and to look for any side effects.
Your doctors and nurses will closely monitor you throughout the study. The total length of your participation will depend on how you respond to the treatment and how you tolerate it. After you stop taking the study medication, there will be follow-up appointments to continue monitoring your health and collect important information. The study will last until enough information has been gathered, which could be for several months or even longer.
Potential risks and benefits
Locations (5)
- —UnverifiedRomania
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedCzechia
- —UnverifiedFrance
Common questions
What type of cancer is this study for?
This study is for people who have advanced liver cancer, specifically hepatocellular carcinoma.
What medicines are being tested?
The study is testing a combination of two medicines: nivolumab (Opdivo) and relatlimab.
Why are these particular medicines being used together?
Both medicines work with your immune system to fight cancer, and researchers hope combining them will be more effective.
What does 'advanced' liver cancer mean in this study?
It means the cancer has progressed or grown even though you've already received other treatments called tyrosine kinase inhibitors.
Will I know which treatment I'm getting?
Yes, this is an 'open-label' study, meaning both you and your doctor will know what medicines you are receiving.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.